Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)

Science Translational Medicine

Volumn 4, Issue 154, 2012, Pages

  Goncharova, Elena A ^a   Goncharov, Dmitry A ^a   Fehrenbach, Melane ^a   Khavin, Irene ^a   Ducka, Blerina ^a   Hino, Okio ^b   Colby, Thomas V ^c   Merrilees, Mervyn J ^d   Haczku, Angela ^a   Albelda, Steven M ^a,e   Krymskaya, Vera P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; RAPAMYCIN; SIMVASTATIN; STROMELYSIN; VASCULOTROPIN D;

AIRSPACE ENLARGEMENT; ALVEOLAR DESTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; LUNG LESION; LUNG LYMPHANGIOLEIOMYOMATOSIS; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUBEROUS SCLEROSIS COMPLEX 1 GENE; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; SIMVASTATIN; SIROLIMUS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84867229035     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003840     Document Type: Article

References (50)

1. S. C. Juvet, F. X. McCormack, D. J. Kwiatkowski, G. P. Downey, Molecular pathogenesis of lymphangioleiomyomatosis: Lessons learned from orphans. Am. J. Respir. Cell Mol. Biol. 36, 398-408 (2007).
2. S. L. Dabora, S. Jozwiak, D. N. Franz, P. S. Roberts, A. Nieto, J. Chung, Y. S. Choy, M. P. Reeve, E. Thiele, J. C. Egelhoff, J. Karprzyk-Obara, D. Domanska-Pakiela, D. J. Kwiatkowski, Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68, 64-80 (2001).
3. R. Zoncu, A. Efeyan, D. M. Sabatini, mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011).
4. E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall, M. N. Hall, Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128 (2004).
5. A. Saci, L. C. Cantley, C. L. Carpenter, Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol. Cell 42, 50-61 (2011).
6. E. Goncharova, D. Goncharov, D. Noonan, V. P. Krymskaya, TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J. Cell Biol. 167, 1171-1182 (2004).
7. E. A. Goncharova, D. A. Goncharov, P. N. Lim, D. Noonan, V. P. Krymskaya, Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 34, 473-480 (2006).
8. E. A. Goncharova, D. A. Goncharov, H. Li, W. Pimtong, S. Lu, I. Khavin, V. P. Krymskaya, mTORC2 is required for proliferation and survival of TSC2-null cells. Mol. Cell. Biol. 31, 2484-2498 (2011).
9. P. S. Lee, S. W. Tsang, M. A. Moses, Z. Trayes-Gibson, L. L. Hsiao, R. Jensen, R. Squillace, D. J. Kwiatkowski, Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am. J. Respir. Cell Mol. Biol. 42, 227-234 (2010).
10. W. Y. C. Chang, D. Clements, S. R. Johnson, Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 299, L393-L400 (2010).
11. L.M.Moir, H. Y.Ng,M. H. Poniris, T. Santa, J. K. Burgess, B. G. G.Oliver, V. P. Krymskaya, J. L. Black, Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br. J. Pharmacol. 164, 83-92 (2011).
12. E. A. Goncharova, D. A. Goncharov, A. Eszterhas, D. S. Hunter, M. K. Glassberg, R. S. Yeung, C. L. Walker, D. Noonan, D. J. Kwiatkowski, M. M. Chou, R. A. Panettieri Jr., V. P. Krymskaya, Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277, 30958-30967 (2002).
13. V. P. Krymskaya, E. A. Goncharova, PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects. Cell Cycle 8, 403-413 (2009).
14. S. J. Marygold, S. J. Leevers, Growth signaling: TSC takes its place. Curr. Biol. 12, R785-R787 (2002).
15. F. X. McCormack, Y. Inoue, J. Moss, L. G. Singer, C. Strange, K. Nakata, A. F. Barker, J. T. Chapman, M. L. Brantly, J. M. Stocks, K. K. Brown, J. P. Lynch III, H. J. Goldberg, L. R. Young, B. W. Kinder, G. P. Downey, E. J. Sullivan, T. V. Colby, R. T. McKay, M. M. Cohen, L. Korbee, A. M. Taveira-DaSilva, H. S. Lee, J. P. Krischer, B. C. Trapnell; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group, Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364, 1595-1606 (2011).
16. V. P. Krymskaya, Treatment option(s) for pulmonary lymphangioleiomyomatosis: Progress and current challenges. Am. J. Respir. Cell Mol. Biol. 46, 563-565 (2012).
17. M. F. Demierre, P. D. R. Higgins, S. B. Gruber, E. Hawk, S. M. Lippman, Statins and cancer prevention. Nat. Rev. Cancer 5, 930-942 (2005).
18. P. J. Barnes, Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc. Am. Thorac. Soc. 5, 857-864 (2008).
19. D. J. Kwiatkowski, Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat. Res. Biol. 8, 51-57 (2010).
20. D. M. Crooks, G. Pacheco-Rodriguez, R. M. DeCastro, J. P. McCoy Jr., J. A. Wang, F. Kumaki, T. Darling, J. Moss, Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. U.S.A. 101, 17462-17467 (2004).
21. T. Kumasaka, K. Seyama, K. Mitani, S. Souma, S. Kashiwagi, A. Hebisawa, T. Sato, H. Kubo, K. Gomi, K. Shibuya, Y. Fukuchi, K. Suda, Lymphangiogenesis- mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am. J. Surg. Pathol. 29, 1356-1366 (2005).
22. D. N. Franz, J. J. Bissler, F. X. McCormack, Tuberous sclerosis complex: Neurological, renal and pulmonary manifestations. Neuropediatrics 41, 199-208 (2010).
23. C. P. Pavlovich, L. S. Schmidt, Searching for the hereditary causes of renal-cell carcinoma. Nat. Rev. Cancer 4, 381-393 (2004).
24. T. Kobayashi, O. Minowa, J. Kuno, H. Mitani, O. Hino, T. Noda, Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res. 59, 1206-1211 (1999).
25. E. A. Goncharova, D. A. Goncharov, M. Spaits, D. J. Noonan, E. Talovskaya, A. Eszterhas, V. P. Krymskaya, Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2. Am. J. Respir. Cell Mol. Biol. 34, 561-572 (2006).
26. E. A. Goncharova, P. Lim, D. A. Goncharov, A. Eszterhas, R. A. Panettieri Jr., V. P. Krymskaya, Assays for in vitro monitoring of proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells. Nat. Protoc. 1, 2905-2908 (2006).
27. S. Hiratsuka, K. Nakamura, S. Iwai, M. Murakami, T. Itoh, H. Kijima, J. M. Shipley, R. M. Senior, M. Shibuya, MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300 (2002).
28. C. C. Hsia, D. M. Hyde, M. Ochs, E. R. Weibel; ATS/ERS Joint Task Force on Quantitative Assessment of Lung Structure, An official research policy statement of the American Thoracic Society/European Respiratory Society: Standards for quantitative assessment of lung structure. Am. J. Respir. Crit. Care Med. 181, 394-418 (2010).
29. W. D. Travis, T. V. Colby, M. N. Koss, M. L. Rosado-De-Christenson, N. L. Müller, T. E. King Jr., AFIP Atlas of Nontumor Pathology: Non-Neoplastic Disorders of the Lower Respiratory Tract (American Registry of Pathology, Washington, DC, 2002), pp. 147-159.
30. T. Kumasaka, K. Seyama, K. Mitani, T. Sato, S. Souma, T. Kondo, S. Hayashi, M. Minami, T. Uekusa, Y. Fukuchi, K. Suda, Lymphangiogenesis in lymphangioleiomyomatosis: Its implication in the progression of lymphangioleiomyomatosis. Am. J. Surg. Pathol. 28, 1007-1016 (2004).
31. L. R. Young, Y. Inoue, F. X. McCormack, Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N. Engl. J. Med. 358, 199-200 (2008).
32. L. Hortobágyi, S. Kierstein, K. Krytska, X. Zhu, A. M. Das, F. Poulain, A. Haczku, Surfactant protein D inhibits TNF-a production by macrophages and dendritic cells in mice. J. Allergy Clin. Immunol. 122, 521-528 (2008).
33. Y. Fukuda, M. Kawamoto, A. Yamamoto, M. Ishizaki, F. Basset, Y. Masugi, Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum. Pathol. 21, 1252-1261 (1990).
34. M. J. Merrilees, E. J. Hankin, J. L. Black, B. Beamont, Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis. J. Pathol. 203, 653-660 (2004).
35. M. D. Sternlicht, Z. Werb, How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516 (2001).
36. G. Pacheco-Rodriguez, F. Kumaki, W. K. Steagall, Y. Zhang, Y. Ikeda, J. P. Lin, E. M. Billings, J. Moss, Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J. Immunol. 182, 1270-1277 (2009).
37. D. F. Lee, H. P. Kuo, C. T. Chen, J. M. Hsu, C. K. Chou, Y. Wei, H. L. Sun, L. Y. Li, B. Ping,W. C. Huang, X. He, J. Y. Hung, C. C. Lai, Q. Ding, J. L. Su, J. Y. Yang, A. A. Sahin, G. N. Hortobagyi, F. J. Tsai, C. H. Tsai, M. C. Hung, IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-455 (2007).
38. V. P. Krymskaya, J. M. Shipley, Lymphangioleiomyomatosis: A complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am. J. Respir. Cell Mol. Biol. 28, 546-550 (2003).
39. T. Hayashi, M. V. Fleming, W. G. Stetler-Stevenson, L. A. Liotta, J. Moss, V. J. Ferrans, W. D. Travis, Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum. Pathol. 28, 1071-1078 (1997).
40. C. G. Glasgow, N. A. Avila, J. P. Lin, M. P. Stylianou, J. Moss, Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 135, 1293-1300 (2009).
41. K. Seyama, K. Mitani, T. Kumasaka, S. K. Gupta, S. Oommen, G. Liu, J. H. Ryu, N. E. Vlahakis, Lymphangioleiomyoma cells and lymphatic endothelial cells: Expression of VEGFR-3 in lymphangioleiomyoma cell clusters. Am. J. Pathol. 176, 2051-2052 (2010).
42. S. L. Dabora, D. N. Franz, S. Ashwal, A. Sagalowsky, F. J. DiMario Jr., D. Miles, D. Cutler, D. Krueger, R. N. Uppot, R. Rabenou, S. Camposano, J. Paolini, F. Fennessy, N. Lee, C. Woodrum, J. Manola, J. Garber, E. A. Thiele, Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 6, e23379 (2011).
43. S. Takahashi, H. Nakamura, M. Seki, Y. Shiraishi, M. Yamamoto, M. Furuuchi, T. Nakajima, S. Tsujimura, T. Shirahata, M. Nakamura, N. Minematsu, M. Yamasaki, H. Tateno, A. Ishizaka, Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L882-L890 (2008).
44. S. Bellosta, D. Via, M. Canavesi, P. Pfister, R. Fumagalli, R. Paoletti, F. Bernini, HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18, 1671-1678 (1998).
45. M. K. Jain, P. M. Ridker, Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977-987 (2005).
46. B. Camoretti-Mercado, Targeting the airway smooth muscle for asthma treatment. Transl. Res. 154, 165-174 (2009).
47. G. A. Finlay, A. J. Malhowski, Y. Liu, B. L. Fanburg, D. J. Kwiatkowski, D. Toksoz, Selective inhibition of growth of tuberous sclerosis complex 2-null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res. 67, 9878-9886 (2007).
48. N. Lee, C. L. Woodrum, A. M. Nobil, A. E. Rauktys, M. P. Messina, S. L. Dabora, Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 9, 8 (2009).
49. S. El-Chemaly, A. Taveira-DaSilva, M. P. Stylianou, J. Moss, Statins in lymphangioleiomyomatosis: A word of caution. Eur. Respir. J. 34, 513-514 (2009).
50. Y. Shang, T. Yoshida, B. A. Amendt, J. F. Martin, G. K. Owens, Pitx2 is functionally important in the early stages of vascular smooth muscle cell differentiation. J. Cell Biol. 181, 461-473 (2008).